.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX16_OportuzumabMonatox.OportuzumabMonatox .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX16_OportuzumabMonatox.OportuzumabMonatox| name: | OportuzumabMonatox | |
| ATC code: | L01FX16 | route: | intravesical |
| compartments: | 1 | |
| dosage: | 30 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Oportuzumab monatox is a recombinant fusion protein consisting of a humanized monoclonal antibody targeting EpCAM (epithelial cell adhesion molecule) fused to a truncated Pseudomonas exotoxin A. It is developed as an anti-cancer agent, specifically for the treatment of non-muscle invasive bladder cancer (NMIBC), targeting EpCAM-expressing tumor cells. The drug is not currently approved for use by regulatory agencies.
No peer-reviewed publication available reporting specific pharmacokinetic parameters for oportuzumab monatox in human populations as of the latest literature review (up to June 2024).